Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zachary Schlei"'
Publikováno v:
JCO Oncol Pract
PURPOSE: Intravenous immunoglobulin (IVIG) is used to replenish immunoglobulins in hypogammaglobulinemia (HG) caused by hematologic malignancies (HM) or their treatment (autologous stem-cell transplantation [ASCT] and chimeric antigen receptor T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edfb30614bd934abce3a737a5e304136
https://doi.org/10.1200/op.20.00312
https://doi.org/10.1200/op.20.00312
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction Rituximab carries a boxed warning for severe or fatal infusion reactions; most occurring with the initial infusion. Prior studies established that if the initial rituximab infusion is tolerated, subsequent infusions can be given safely o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97fcdc61e0f580a5ed10fed3b6d0af08
https://pubmed.ncbi.nlm.nih.gov/35167401
https://pubmed.ncbi.nlm.nih.gov/35167401
Autor:
Andrzej Jakubowiak, Amanda McIver, Sarah Major, Zachary Schlei, Sandeep Parsad, Brittany Wolfe, Jagoda Jasielec, Christine Gleason, Amin Virani, Megan Ackermann
Publikováno v:
Journal of Clinical Oncology. 38:e14030-e14030
e14030 Background: Improvements in cancer treatment, supportive care, and the approval of oral chemotherapy medications over the past decade have resulted in an increasing number of cancer patients treated in outpatient settings. Transitioning cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7448ba58e17a4b514339985997bd65
https://doi.org/10.1200/jco.2020.38.15_suppl.e14030
https://doi.org/10.1200/jco.2020.38.15_suppl.e14030
Publikováno v:
Journal of Clinical Oncology. 38:e19225-e19225
e19225 Background: IVIG is used to replenish immunoglobulins in HG due to hematologic malignancies (HM) or their treatment (stem cell transplantation (ASCT) and chimeric antigen receptor T-cell therapy (CAR-T)), in an effort to reduce the risk of inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3e7e10460250e4424f00dae3228451f
https://doi.org/10.1200/jco.2020.38.15_suppl.e19225
https://doi.org/10.1200/jco.2020.38.15_suppl.e19225
Publikováno v:
Clinical lung cancer. 19(6)
Background Pemetrexed is a folate analog inhibitor for the treatment of non–small-cell lung cancer (NSCLC) and malignant pleural mesothelioma. Folic acid and vitamin B12 supplementation before initiating pemetrexed is necessary because of high rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9116d74b0e9e2ce987d37136271db914
https://pubmed.ncbi.nlm.nih.gov/30143457
https://pubmed.ncbi.nlm.nih.gov/30143457
Publikováno v:
Journal of Clinical Oncology. 34:e21682-e21682
e21682Background: Pemetrexed (Pem) is a folate analog inhibitor considered first line (1L) for advanced non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Bef...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe85acc4c65a2c80850f0a79601c7be2
https://doi.org/10.1200/jco.2016.34.15_suppl.e21682
https://doi.org/10.1200/jco.2016.34.15_suppl.e21682